资源描述:
《贝伐单抗联合化疗治疗非小细胞肺癌的临床研究》由会员上传分享,免费在线阅读,更多相关内容在学术论文-天天文库。
1、贝伐单抗联合化疗治疗非小细胞肺癌的临床研究张琳琳(辽宁省肿瘤医院内五科辽宁沈阳110042)【摘要】目的:研究災伐单抗联合化疗治疗非小细胞肺癌的疗效,探讨W伐单抗联合化疗的治疗价值。方法:将92例非鳞非小细胞肺癌患者随机分为治疗组和对照组各46例,对照组采用培美曲塞联合顺铂的化疗方案化疗,治疗组在对照组的基础上加用災伐单抗治疗,观察两组的治疗效果、生存时间和不良反应发生情况。结果:治疗组有效率47.83%优于对照组的23.91%,χ2=5.718,p<0.05,治疗组受益率为91.30%,优于对照组,
2、χ2=9.200,p<0.01;治疗组无进展生存期、总生存时间、1年生存率、3年生存率、5年生存率均高于对照组,且均有统计学差异(p<0.05);两组不良反应中,治疗组发生略高于对照组,但均无统计学差异(p〉0.05)。结论:贝伐单抗联合一线化疗可从不同作用机制发挥协同治疗的作用,增加化疗对非鱗NSCLC治疗效果,有临床推广价值。【关键词】非小细胞肺癌;贝伐单抗:化疗【中图分类号1R734.2【文献标识码】B【文章编号】1003-5028(2015)8-0618-01ClinicalStudyonth
3、eBevacizumabCombinedwithChemotherapyintheTreatmentofNon-smallCellLungCancerZhangLinlin(InternalMedicine5,LiaoningProvinceCancerHospital,Shenyang,Liaoning,China,110042)【Abstract】Aim:TostudytheclinicaleffectandapplicatoinvalueofBevacizumabcombinedwithchemothe
4、rapyinthetreatmentofnon-smallcelllungcancerCNSCLC).Methods:92casesofadvancednon-squamousNSCLCweredividedintothetreatmentgroup(n=46cases)andthecontrolgroup(n=46cases).Thecontrolgroupreceivedchemotherapy(pemetrexed+cisplatin)andthetreatmentgroupwasgivedgivenb
5、evacizumab+pemetrexed+cisplatin.Thetherapyeffect,totalsurvivaltimeandadversereactionwereobservedandcompared.Results:Theresponserateandclinicalbeneficialrateofthetreatmentgroupwere=higherthanthoseof=controlgroupwithsignificantdifferences(χ2=5.718,9.200,p
6、<0.05).Theprogressionfreesurvivaltime,overallsurvival,oneyearsurvivalrate,threeyearssurvivalrateandfiveyearssurvivalratewerehigherthanthoseofcontrolgroupwithsignificantdifferences(p<0.05).Theadversereactionsincidenceratehadnostatisticalsignificancebetweentr
7、eatmentgroupandcontrolgroup(p〉0.05).Conclusion:Theshort-termandlong-termefficacyofcombinedwithfirst-linechemotherapyweresuperiortofirst-linechemotherapyinthetreatmentofadvancednon-squamousNSCLC,whichcouldenhancethetherapeuticeffectofchemotherapythroughmulti
8、plepathways.【KeyWords】No-smallCellLungCancer;Bevacizumab;Chemotherapy所有的恶性肿瘤中,肺癌的发病率最高,报道显示,全世界每年有1200万患者的死亡原因是肺癌[1】。肺癌的病理类型中,非小细胞肺癌(non-smallcelllungcancer,NSCLC)发病约占80%〜85%,大部分NSCLC患者就诊吋已处于晚期,失去手术时间,